Echo starts clinical trial of one-piece biosensor for diabetes
This article was originally published in Clinica
Echo Therapeutics has begun a clinical trial of a one-piece version of its noninvasive wireless Symphony transdermal continuous glucose monitoring (tCGM) system in patients with type 1 and 2 diabetes. Earlier studies used a prototype two-piece biosensor, and Echo (Franklin, Massachusetts) hopes that the new device will show "improved performance and reliability". The trial, which is expected to report results this quarter, will also evaluate the company's Prelude skin preparation system for transdermal drug delivery. It will collect approximately 900 data pairs from diabetes patients, and compare results from the Symphony system with the gold-standard YSI Glucose Analyzer.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.